This trial is active, not recruiting.

Conditions alveolar bone loss, periodontal bone loss
Treatments md05 and open flap debridement, open flap debridement
Phase phase 2
Sponsor Scil Technology GmbH
Collaborator FGK Clinical Research GmbH
Start date July 2007
End date October 2008
Trial size 20 participants
Trial identifier NCT00519155, EudraCT-No.: 2006-005883-25, Scil-MD05-C02


The purpose of the study is to gain experience of safety and efficacy with MD05 in man in alveolar bone regeneration.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Open flap debridement + MD05
md05 and open flap debridement
recombinant human GDF-5 coated onto ß-tricalcium phosphate
(Active Comparator)
Open flap debridement
open flap debridement
Open flap debridement alone

Primary Outcomes

Evidence of regeneration of alveolar bone.
time frame: October 2008

Secondary Outcomes

Evidence of uncompromised healing.
time frame: October 2008

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Patients requiring extraction of teeth with advanced intrabony periodontal defects at single rooted teeth without root concavities/furrows located in the maxilla and mandible (maxillary/mandibular premolars, maxillary incisors; presurgery probing depth ≥ 6 mm, intrasurgery defect depth ≥ 4 mm) or located the mesial or distal aspect of mandibular molar teeth without adjacent teeth (excluding defects also involving the furcation area). - Teeth to be treated must be scheduled for extraction in a treatment plan established by clinicians unrelated to the study. - Male and female patients, aged 18 - 75 years - Patients must be non-smokers - Female patients must be infertile (either sterilized or postmenopausal). If a patient's menopausal status at screening is uncertain, levels of follicle stimulating hormone (FSH) should be determined. Patients with an FSH level > 25 IU/l and absence of menstrual bleeding > 6 months will satisfy the definition of postmenopausal status. - Patient must provide written informed consent Exclusion Criteria: - Women of childbearing potential, pregnant or lactating women - Participation in another clinical study within 30 days prior to study start - Previous participation in this study - Legal incompetence or restricted legal competence - Alcoholism, drug dependency, smoking - Acute or chronic infection at the application site - Known infection with HIV, HBV, or HCV - Severe allergic rhinitis which requires permanent medication - Known intolerance of or hypersensitivity to ß-TCP or rhGDF?5 - Presence of local or systemic malignant disease or history of local or systemic malignant disease in the past 5 years. - Patients requiring chemo- or radiotherapy - Previous or current radiotherapy of the head - Chronic liver disorder (AST and/or ALT over 2 times upper limit of normal) - Impaired renal function (creatinine over 1.5 times upper limit of normal) - Uncontrolled insulin-dependent diabetes mellitus (HbA1c > 7%) - Clinically relevant symptoms of thyroid dysfunction - Severe hypertension (RRdiast > 110 mmHg) - Clinically relevant cardiovascular disease e.g., decompensated cardiac insufficiency, hemodynamically relevant heart valve defects, or myocardial infarction during the last three months - Systemic bone disease or illness having influence in bone metabolism (e.g. Osteogenesis imperfecta, Paget's disease, Ehlers-Danlos disease, osteomalacia, renal osteodystrophia, hyperparathyroidism) - Clinically relevant blood coagulation disorder - Leukopenia < 3.500 leukocytes/µL - Previous (within last 2 months before screening visit) or current treatment with systemic corticosteroids of more than 5 mg/day prednisone equivalent - Previous or current therapy with drugs having any influence on bone metabolism such as calcitonin or parathormone (as teriparatid) within the last 6 months before screening visit, bisphosphonates or fluoride at least for 30 days within the last 12 months before screening visit - Previous (within last 2 months before screening visit) or current treatment with immunosuppressant

Additional Information

Official title Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects
Principal investigator Anton Sculean, Prof.
Trial information was received from ClinicalTrials.gov and was last updated in April 2008.
Information provided to ClinicalTrials.gov by Scil Technology GmbH.